ESC 2021 | Empagliflozin in Heart Failure with Reduced and Preserved Ejection Fraction

The full results of the EMPEROR-Preserved study confirm as findings that empagliflozin decreases the risk of death or hospitalization for heart failure (HF) in both patients with reduced and with preserved function.

ESC 2021 | Empagliflozina en insuficiencia cardíaca con función deteriorada y preservada

The primary endpoint (a composite of death and hospitalization for HF) was reduced by 21% on a relative basis with sodium/glucose cotransporter 2 inhibitor or SGLT2 (13.8% vs. 17.1%; hazard ratio [HR]: 0.79; 95% confidence interval [CI]: 0.69 to 0.90). This difference was mainly driven by the reduction in hospitalizations. To avoid an event, 31 patients need to be treated.

These results, presented at the European Society of Cardiology (ESC)  2021 Congress and simultaneously published in NEJM, are the first in history to show the benefits of a drug on patients with heart failure—both with preserved and reduced ejection fraction.

A positive work on HF with preserved fraction had not been published for at least 15 years.

In other previous studies (EMPEROR-Reduced and DAPA-HF), empagliflozin and other SLGT2 inhibitors had shown a reduction in clinical events in patients with reduced ejection fraction.

However, so far no work had been dedicated to patients with preserved ejection fraction.

EMPEROR-Preserved randomized 5988 patients with functional class II-IV and ejection fraction >40% (mean age 75 years and mean ejection fraction 54%) to 10 mg of empagliflozin QD vs. placebo (with all other optimal medication, in all cases). Almost half of the included patients had a diagnosis of diabetes.


Read also: ESC 2021 | COVERT-MI: Colchicine Attempts to Reduce Infarct Size.


The observed reduction in the primary endpoint was mostly attributed to fewer first and subsequent hospitalizations due to heart failure (407 vs. 541; HR: 0.73; 95% CI: 0.61 to 0.88).

This work also showed a slowing deterioration of renal function compared with the placebo.

The most common adverse events were uncomplicated urinary tract infection and hypotension.

NEJM also published the results of EMPEROR-Reduced (which included patients with HF and reduced ejection fraction).


Read also: ESC 2021 | ISAR-REACT 5: Prasugrel Superior to Ticagrelor in ACS across Kidney Function Spectrum.


Overall, the results showed a consistent reduction of events in both EMPEROR studies with a 30-% reduction in hospitalizations in the ejection fraction range between <25% and 65%.

Renal protection was more evident and significant for patients with ejection fraction below 50% (p = 0.02).

EMPEROR-Preserved Emperor

Original Title: Empagliflozin in heart failure with a preserved ejection fraction. EMPEROR-Preserved Trial Investigators

Reference: Presentado por Anker SD en el ESC 2021 y publicado simultáneamente en NEJM.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

STEACS and the Use of Bivalirudin vs. Heparin: In Search of BRIGHT-4 Outcomes

Various studies and registries have previously shown the impact of post-percutaneous coronary intervention (PCI) complications on the survival of patients with ST-segment elevation acute...

TAVR and Atrial Fibrillation: What Anticoagulants Should We Use?

The prevalence of atrial fibrillation (AF) in TAVR patients ranges from 15 to 30%, depending on series. This arrhythmia has been associated to higher...

Ultrathin vs Thin-Strut Stents in PCI Patients at High Bleeding Risk

Several in vivo studies have shown that ultrathin stents present lower thrombogenic risk vs. thin-strut stents, which reflects in lower rates of target lesion...

Should We Withdraw Anticoagulation Before TAVR?

Approximately one-third of patients undergoing transcatheter aortic valve replacement (TAVR) have atrial fibrillation and are on oral anticoagulant (OAC) therapy. This creates a complex...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...